Skip to main content
Download PDF

Exosomes derived from mesenchymal stem cells primed with disease-condition-serum improved therapeutic efficacy in a mouse rheumatoid arthritis model via enhanced TGF-β1 production

Stem Cell Research & Therapy volume 14, Article number: 283 (2023) Cite this article

Abstract

Backgrounds

Rheumatoid arthritis (RA) is a chronic and systemic autoimmune disease characterized by synovial inflammation-mediated progressive destruction of the cartilage and bone, resulting in reduced quality of life. We primed human telomerase reverse transcriptase-overexpressing immortalized human adipose tissue-derived mesenchymal stem cells (iMSCs) with serum derived from a non-human primate RA model and studied the immunomodulatory ability of exosomes obtained from primed iMSCs.

Methods

After immunophenotyping, nanoparticle tracking analysis, and in vitro functional tests, Dulbecco’s phosphate-buffered saline (dPBS, Group C), exosomes derived from the supernatant of iMSCs (Exo-FBS, Group E), exosomes derived from the supernatant of iMSCs primed with RA serum (Exo-RA, Group F), and methotrexate (Group M) were administered in collagen-induced arthritis (CIA) model mice. dPBS was administered to the normal (N) group for comparison (n = 10/group).

Results

Exo-RA had a significantly higher number of exosomes compared to Exo-FBS when measured with nanoparticle tracking analysis or exosome marker CD81, and Transforming growth factor-β1 amounts were significantly higher in Exo-RA than in Exo-FBS. When Exo-FBS or Exo-RA was administered to the collagen-induced arthritis model, serum interleukin (IL)-4 and the proportion of Th2 (CD4+CD25+GATA3+) and M2 (CD11c − CD206+ of CD45+CD64+) cells were significantly increased compared to the control group. Furthermore, Exo-RA could alleviate cartilage damage by significantly lowering the concentrations of proinflammatory cytokines such as tumor necrosis factor-α, keratinocyte chemoattractant, and IL-12p70.

Conclusion

Exosomes derived from disease-condition-serum-primed iMSCs ameliorated cartilage damage in a RA model by enhancing TGF-β1 production, inducing Th2 and M2 polarization and lowering proinflammatory cytokines, TNF-α, KC, and IL-12p70 in the host. Patient-derived serum can be used as an iMSC priming strategy in iMSC-derived exosome treatment of RA.

Introduction

Rheumatoid arthritis (RA) is a chronic and systemic autoimmune disease characterized by synovial inflammation-mediated progressive destruction of the cartilage and bone, resulting in reduced quality of life. [1]. Currently, methotrexate is the most basic drug for the treatment of rheumatoid arthritis [2]. The side effects of methotrexate are similar to those of other common anticancer drugs [3]. One of the biggest problems in using methotrexate is the development of methotrexate resistance [2]. Several patients do not respond to methotrexate or other antirheumatic drugs (antimalarial drugs, sulfasalazine, and leflunomide). In addition, TNF-α inhibitors, ranked 1st, 2nd, and 3rd in sales in the global biopharmaceutical market, are associated with allergic reactions and reduced efficacy due to anti-drug antibodies [4, 5]. Therefore, it is necessary to develop next-generation treatments that can reduce or replace the existing treatment capacity.

The interactions between mesenchymal stem cells (MSCs) and the host microenvironment regulate the secretion of MSCs. Soluble factors and exosomes from MSCs induce immunomodulatory properties [6]. MSC-based therapy has shown beneficial effects in various animal models of autoimmune diseases and several human clinical trials [7, 8].

Paracrine actions vary depending on the source of the MSCs, target cells, and the microenvironment surrounding the cells [9]. In a previous study, plasma from patients with graft-versus-host disease significantly enhanced the immunosuppressive potential of MSCs. In addition, plasma interferon (IFN)-γ/interleukin (IL)-10 ratio showed a direct correlation with the induction of regulatory T cell (Treg) and immunosuppressive potential [10].

Some risks have been reported with MSC: intra-arterial injection of MSCs has been shown to result in myocardial microinfarction [11], and senescence and loss of stemness of MSCs are major obstacles in clinical application [12, 13].

MSC-derived exosomes (MSC-exosomes) contain various mRNA, miRNAs, and proteins originating from the parent MSCs [14], and display immunoregulatory functions similar to the parent MSCs [15]. MSC-exosomes are 50–150 nm in size [14]; thus, they do not cause micro-infarction problems. MSC-exosomes are stable and easy to store and transport [16]. MSC-exosomes have no risk of immune attack, which is an increasing challenge in MSC transplantation [17, 18].

Telomerase maintains the length of the telomere; hence, it plays an important role in the pluripotency and self-renewal potential of embryonic stem cells [19]. However, the MSCs do not exhibit telomerase activity [20]. The introduction of telomerase into normal human cells induces senescence bypassing and extending the lifespan of cells [21]. Furthermore, the overexpression of human telomerase reverse transcriptase (hTERT) in human MSCs increases stemness and inhibits spontaneous differentiation [13].

In the present study, hTERT-overexpressing immortalized human adipose tissue-derived MSCs (iMSCs) were used to obtain exosomes. We primed iMSCs with serum derived from a non-human primate RA model and studied the immunomodulatory ability of exosomes obtained from the iMSCs primed with disease-condition-serum.

Methods

iMSC culture

iMSCs were purchased from ATCC (SCRC-4000) and maintained in MSC basal medium (PCS-500-030, ATCC) using an MSC growth kit for adipose and umbilical MSCs (PCS-500-040, ATCC) according to the manufacturer’s instructions. De-identified human iMSCs were used in this study with an institutional review board (IRB)-approved exemption (KWNUIRB-2021-04-009-001).

Immunophenotype characteristics and differentiation capacity of iMSCs

The immunophenotypic characteristics of the iMSCs were analyzed as described in our previous study. iMSCs were seeded at a density of 4.5 × 104 cells/well in a 12-well plate for adipogenesis and osteogenesis. After 4 days, the iMSCs were maintained in adipogenic induction medium (Mesenchymal Adipogenesis Kit, Millipore, Burlington, Massachusetts, USA) or osteogenic induction medium (OsteoDiff Media, StemMACS™, Millipore) for up to 3 weeks, with fresh medium changed every third day. Adipogenesis and osteogenesis were confirmed by staining with Oil Red O (Mesenchymal Adipogenesis Kit; Millipore SCR020) and Alizarin Red S (A5533; Sigma-Aldrich), respectively. For chondrogenesis, 1 × 106 iMSCs were centrifuged in a 15 mL tube to form a pellet, differentiated using cartilage differentiation medium for up to 3 weeks, with fresh media changed every third day (MSC Chondrogenic Differentiation Medium, Promocell, Heidelberg, Germany), fixed in formalin, paraffin-sectioned, and stained with toluidine blue to confirm chondrogenesis.

Exosome production and characterization

For exosome production, iMSCs were seeded in DMEM supplemented with 2 mmol/mL glutamine, 100 μg/mL penicillin/streptomycin, and 10% fetal bovine serum (FBS) at a density of 107 per 175 T flask (about 6 × 104 cells/cm2) for 24 h, and then incubated in DMEM supplemented with 2 mmol/mL glutamine, 100 μg/mL penicillin/streptomycin, and 10% Exosome-depleted FBS (A2720801, Gibco, Grand Island, NY, USA) for 48 h (MSC-FBS). Stored serum samples obtained from non-human primates before the induction of RA (non-RA serum) or during an autopsy after the induction of RA (RA-serum) in a previous non-human primate RA experiment (not yet published; ORIENT-IACUC-21110) were used for priming iMSCs. iMSCs were seeded in DMEM supplemented with 2 mmol/mL glutamine, 100 μg/mL penicillin/streptomycin, 2 mmol/mL glutamine, and 17.5% non-RA or RA serum at a density of 107 per 175 T flask for 24 h, and then incubated in DMEM supplemented with 2 mmol/mL glutamine, 100 μg/mL penicillin/streptomycin, and 10% exosome-depleted FBS for 48 h (MSCs primed with RA serum: MSC-RA).

Exosomes derived from the supernatant of iMSCs (Exo-FBS), iMSCs primed with RA serum (Exo-RA), or non-RA serum (Exo-non-RA) were isolated using the Total Exosome Isolation Reagent (4478359, Invitrogen, Waltham, Massachusetts, USA) according to the manufacturer’s instructions.

The total protein concentration of exosomes was determined by bicinchoninic acid (BCA) assay (BCA protein assay kit™, Pierce), and the size distribution of exosomes was determined by nanoparticle tracking analysis (NTA) using a NanoSight NS300 instrument (Malvern Instruments Ltd., Worcestershire, UK). The morphology of the exosomes was observed using a transmission electron microscopy (TEM) and the expression of CD81 was analyzed using an ExoELISA-ULTRA Complete Kit (EXEL-ULTRA-CD81-1, SBI, Palo Alto, CA, USA).

ELISA for determination of the concentration of transforming growth factor (TGF)-β1, prostaglandin E2 (PGE2), and IL-1ra in exosomes

The concentrations of TGF-β1, PGE2, and IL-1Ra in exosomes (Exo-FBS and Exo-RA) were assessed using human LAP (TGF-β1) Quantikine ELISA Kit, Prostaglandin E2 Parameter Assay Kit, and Human IL-1ra/IL-1F3 Quantikine ELISA Kit (R&D systems, Minneapolis, MN, USA), respectively.

Expression levels of MicroRNA (miR)-155-5p, miR-146a-5p, miR-10-5p, miR-142-3p and miR-216a-5p in exosome and iMSCs

miRNAs were isolated from exosomes (Exo-FBS and Exo-RA) and iMSCs using a Total Exosome RNA Protein Isolation Kit (Invitrogen, Waltham, Massachusetts, USA) and Tri-Reagent (MRC), respectively. cDNA was generated using the miRCURY LNA RT kit (Qiagen, Venlo, Netherlands), and qPCR was performed using the miRCURY LNA SYBR Green PCR kit with several miScript primers (Qiagen): hsa-miR-16a-5p, hsa-miR-155-5p, hsa-miR-146a-5p, hsa-miR-10a-5p, hsa-miR-142-3p, and hsa-miR-216a-5p. qPCR was performed according to the protocol provided by the manufacturer. miR-16-5p served as the housekeeping gene and the 2−ΔΔCT method was used to determine expression levels.

In vitro functional test

Experimental animals

Three seven-week-old male DBA/1 mice were obtained from Orient Bio (Gayang, Korea) and acclimatized for one week before the study commenced. This animal study was reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of Kangwon National University (KW-210824-1).

Chicken type II collagen (CII, Sigma-Aldrich, Burlington, Massachusetts, USA) was used to induce collagen-induced arthritis (CIA). The concentration, preparation, and administration of CII were as described previously [22]. Mice were administered a booster dose three weeks post-first CII administration (Sigma-Aldrich).

ELISA of multiple cytokines in supernatants of spleen-cell culture obtained from the mice with CIA

Spleen cells from each mouse were isolated on day 48 after CII immunization and cultured as described previously, with or without denatured CII (100 μg/mL), ConA (5 μg/mL), or LPS (2.5 μg/mL) [22]. Each well was treated with the medium (no treatment), Exo-FBS, Exo-RA, or Exo-non-RA. Exosomes and splenocytes were co-cultured at a ratio of 9 μg:2 × 105. This ratio was determined based on a previous study [1]. After culturing for 72 h at 37 °C in a humidified atmosphere, the culture supernatant was collected and stored at -80 °C. Cytokines were measured with the mouse multiplex MAP Kits using the Luminex technology [22].

In vivo test

Experimental animals

Fifty seven-week-old male DBA/1 mice were purchased from Orient Bio (Gayang, Korea) and acclimatized for one week before the commencement of the study. This study was reviewed and approved by the IACUC of GenNBio (GN-IACUC-22-01-10).

Experimental groups and induction of CIA

To compare the therapeutic effects of Exo-FBS and Exo-RA in the CIA mouse model, experimental mice were divided into five groups (n = 10 mice per group): normal (N), control (C), Exo-FBS (E), Exo-RA (F), and MTX (M). Mice in the other groups, except the N group, were induced with CIA as described for the in vitro functional test.

Treatment protocol

Each mouse in the N and C groups was intravenously administered 150 μL of dPBS, whereas those in the E group were intravenously administered with exosomes derived from the supernatant of 2 × 106 iMSCs (Exo-FBS)/150 μL of dPBS. The F group were intravenously administered with exosomes derived from the supernatant of 2 × 106 iMSCs primed with RA serum (Exo-RA)/150 μL of dPBS twice a week (on days 25, 29, 32, 33, 39, 43, 46, and 50 after CII immunization).

Each mouse in the M group was intraperitoneally administered 3 mg/kg methotrexate (Medac, Hamburg, Germany) three times per week (on days 23, 25, 28, 30, 32, 35, 37, 39, 42, 44, 46, 49, and 51 after CII immunization). All mice were sacrificed on days 52–53 after CII immunization.

Arthritis severity assessment

The paw thickness of each mouse was measured weekly with a caliper. The arthritis score was evaluated from 0 (no arthritis) to 4 (severe arthritis) thrice per week starting from day 21 post-CII immunization, as described previously [22]: score 0: normal paw; score 1: one or two toes inflamed and swollen; score 2: three or more toes inflamed and swollen; score 3: swelling of the entire paw; score 4: severe swelling of the entire paw and all toes, or ankylosed paw and toes.

The detection of anti-CII antibody and C-telopeptide of type II collagen (C-telopeptide II) levels

Mice were anesthetized (isoflurane) and sacrificed, and blood samples were collected on day 52 or 53 after CII immunization. The collected sera were stored at − 80 °C until use. Antibodies against chicken CII and mouse CII were measured using a commercial mouse anti-chicken CII ELISA kit (2031, Chondrex Inc., Redmond, WA, USA) and a commercial mouse anti-mouse CII ELISA kit (2036, Chondrex). Serum C-telopeptide II levels were measured in the same way as in the previous paper [23].

T cell proliferation test using splenocytes from experimental animals

On day 52 or 53, the spleens were harvested from all mice. Splenocytes from each mouse were cultured in a 96-well plate (density: 2 × 105 cells/well and final volume: 200 μL) with or without CII, ConA, or LPS (100 μg/mL, 5 μg/mL, and 2.5 μg/mL respectively). Plates were incubated at 37 °C in 5% CO2. After 3 days, a BrdU assay was performed (BrdU labeling time: 6 h) using a commercial kit (Cell Proliferation ELISA BrdU, Colorimetric; Roche Diagnostics, Mannheim, Germany). The stimulation index values (mean optical density of CII- or mitogen-stimulated cultures/mean optical density of medium-only cultures) were calculated for each culture treatment.

Flow-cytometric determination of T cell subset, CD138 cells, and macrophage subset in the spleen

Splenocytes were obtained from the spleens of DBA/1 mice at autopsy (on day 52 or 53 after CII immunization). An Fc-blocking antibody was used to prevent nonspecific binding (anti-mouse CD16/32; BioLegend, San Diego, CA, USA). Splenocytes were stained with peridinin chlorophyll protein complex-conjugated anti-mouse CD45 (1.25 μL/well, BioLegend), allophycocyanin-conjugated anti-mouse CD3e (1 μL/well, eBioscience, San Diego, CA, USA), fluorescein isothiocyanate conjugated anti-mouse CD4 (2 μL/well, BD Biosciences), and phycoerythrin (PE)-cyanine7-conjugated anti-mouse CD8a (0.5 μL/well, eBioscience). The fraction of CD138-positive cells was analyzed (PE rat anti-mouse CD138, 1 μL/well, BD Biosciences) as described previously [24].

The macrophage subset, the proportion of proinflammatory M1 macrophages (CD45+CD64+CD11c+CD206−) and anti-inflammatory M2 macrophages (CD45+CD64+CD11c−CD206+), was also analyzed as described previously [25].

Flow-cytometric analysis of the T helper cell subset in the spleen

The proportions of Treg cells (CD4+CD25+Foxp3+), Th17 cells (CD4+CD25+ROR-γt+), Th1 cells (CD4+CD25+T-bet+), and Th2 cells (CD4+CD25+GATA-3+) were analyzed as described previously [22, 24].

Histopathology

Knee joint tissue sections were stained and cartilage damage was evaluated as described previously [23], and the severity of cartilage damage was graded from 0 (none) to 4 (severe). The knee joints were harvested for histopathological examination after fixation in 10% neutral-buffered formalin, decalcified, and embedded in paraffin.

Various cytokines in sera and knee joint extracts

Serum and joint extract samples from all mice were used for the analysis of TNF-α, IFN-γ, IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-10, IL-12p70, IL-17, KC, MCP-1, MIP-2, and RANTES with multiplex® MAP Kits (Millipore, Bedford, MA, USA).

Briefly, 12.5 μL of dPBS containing protease inhibitor was added per 1 mg of knee joint sample and homogenized using an automated freeze-crushing cell homogenizer as described in our previous study [23]. Total protein concentrations in the joint extracts were determined using a BCA protein assay kit (Pierce). The total protein concentration of knee joint extracts was adjusted to 2 mg/dL and used for analysis.

Statistical analysis

All results are expressed as mean ± the standard error of the mean (SEM). The results of the four groups, except for the cytokine data, were compared using one-way analysis of variance (ANOVA), followed by Tukey’s multiple comparison post-hoc tests. Cytokine data were analyzed using Kruskal–Wallis and Dunn’s tests. To compare the means of two related samples, Paired t-test was used. p < 0.05 was considered significant. All statistical analyses were performed using SPSS version 26.0 (SPSS, Armonk, NY, USA).

Results

iMSC immunophenotyping and differentiation

As a result of immunophenotyping using flow cytometry, iMSC showed positive expression of CD29, CD44, CD73, CD90, and CD105, and absence of CD31, CD34, CD45, and HLA-DR (Fig. 1A). Features indicating the differentiation of iMSCs into adipocytes, osteocytes, and chondrocytes are shown in Fig. 1B–G.

Fig. 1
figure 1

Immunophenotype and differentiation of immortalized mesenchymal stem cells (iMSCs) into adipocytes, osteocytes, and chondrocytes. A Immunophenotype of iMSCs B iMSC negative control, oil red-O stain × 100 C iMSCs that differentiated into adipocytes contained lipid droplets, oil red-O stain × 100 D iMSC negative control, Alizarin red S stain × 100 E iMSCs differentiated into osteocytes, Alizarin red S × 100; Scale bar = 100 μm F Aggregated chondrocytes derived from iMSCs, toluidine blue × 100; Scale bar = 100 μm G Aggregated chondrocytes derived from iMSCs, toluidine blue × 200; Scale bar = 50 μm

Full size image

Exosome characterization

Female cynomolgus monkeys, approximately 3 years of age and weighing 2–3 kg, were used as non-human primates to obtain disease-conditioned serum. The cynomolgus monkey RA model was established as previously described [26]. In female cynomolgus monkeys under respiratory anesthesia, serum obtained before inducing the RA model was used as non-RA serum, and serum obtained during an autopsy after establishing the RA model was used as RA-serum. Exosomes derived from the supernatant of iMSCs (Exo-FBS), iMSCs primed with RA serum (Exo-RA), or non-RA serum (Exo-non-RA) were isolated using Total Exosome Isolation Reagent. The approximate shape and size were confirmed by photographing with TEM (Fig. 2A, B), and the size distribution was confirmed using NTA.

Fig. 2
figure 2

Characterization of Exosomes. A Transmission electron microscope analysis of freshly isolated exosomes in distilled water; Scale bar = 200 nm B Transmission electron microscope analysis of freshly isolated exosomes in methanol; Scale bar = 100 nm. Exosomes derived from the supernatant of iMSCs (Exo-FBS) or iMSCs primed with RA serum (Exo-RA) or non-RA serum (Exo-non-RA) C Total CD81 of exosome produced from 107 iMSCs D Total number of exosomes produced from 107 iMSCs as determined by NTA (n = 5) E Size of exosomes produced from 107 MSCs as determined by NTA (n = 5) (F) Amounts of TGF-β in exosomes produced from 107 iMSCs G Amounts of IL-1Ra in exosomes produced from 107 iMSCs H Amounts of PGE2 in exosomes produced from 107 iMSCs. (I) Relative expression of miR 155-5p in the exosomes. J Relative expression of miR 146-5p in exosomes. K Relative expression of miR 10-5p in exosomes. L Relative expression of miR 142-3p in exosomes. M Relative expression of miR 155-5p in iMSCs. N Relative expression of miR 146-5p in iMSCs. O Relative expression of miR 10-5p in iMSCs. P Relative expression of miR 142-3p in iMSCs. Q Relative expression of miR 216a-5p in iMSCs. Data (mean ± standard error of the mean) were compared using one-way analysis of variance followed by Tukey’s multiple comparison post-hoc tests.*, Significant differences (p < 0.05) from the Exo-FBS. iMSCs: immortalized mesenchymal stem cells, NTA: Nanoparticle Tracking Analysis, miR: micro RNA

Full size image

The total amount of CD81 produced from 107 iMSCs was 8.1 × 1011 in Exo-FBS, 12.3 × 1011 in Exo-RA, and 8.6 × 1011 in Exo-non-RA. The total amount of CD81 was significantly higher in Exo-RA than in Exo-FBS or Exo-non-RA (ANOVA & Tukey’s test, p < 0.001; Fig. 2C).

NTA revealed that the total number and size of exosomes produced from 107 iMSCs was 3.25 × 1010 in Exo-FBS with an average size of 134.4 nm, 5.94 × 1010 in Exo-RA with an average size of 112.4 nm, and 4.13 × 1010 in Exo-non-RA with an average size of 123.8 nm; the number of exosomes was the highest and size was the smallest in Exo-RA (Fig. 2D, E).

ELISA for determination of the concentration of TGF-β1, prostaglandin E2, and IL-1Ra in exosomes

Analysis of exosomes produced from 107 iMSCs revealed that the amount of TGF-β1 was 15,376.4 ± 1693.2 pg in Exo-FBS and 27,242.4 ± 1564.8 pg in Exo-RA; the amount of TGF-β1 was significantly higher in Exo-RA than in Exo-FBS (Student's t-test, p = 0.036; Fig. 2F).

Analysis of exosomes produced from 107 iMSCs revealed that the amount of IL-1Ra was 24.9 ± 3.9 pg in Exo-FBS and 27.0 ± 2.5 pg in Exo-RA (Fig. 2G). The amount of prostaglandin E2 (PGE2) levels was 152.3 ± 3.9 pg in Exo-FBS and 162.8 ± 8.3 pg in Exo-RA (Fig. 2H).

Expression levels of miR-155-5p, miR-146a-5p, miR-10-5p, miR-142-3p, and miR-216a-5p in exosomes and iMSCs

There were no statistically significant differences in the expression levels of miR-155-5p, miR-146a-5p, miR-10-5p, and miR-142-3p between the equal concentration of RNA extracted from Exo-FBS and Exo-RA (Fig. 2I–L). There was no statistically significant difference in the expression levels of miR-155-5p, miR-146a-5p, miR-10-5p, miR-142-3p, and miR-216a-5p between equal concentrations of RNA extracted from MSC-FBS and MSC-RA (Fig. 2M–Q).

In vitro functional test

The levels of IL-6, IL-17, IL-4, IFN-γ, IL-2, and MCP-1 were analyzed in the supernatants of ConA-stimulated splenocytes, and the levels of TNF-α, KC, IL-10, IL-1α, IL-1β, MIP-2, IL-12p70, and RANTES were analyzed in LPS-stimulated splenocytes.

The levels of RANTES were significantly lower (paired t-test, p = 0.007) and the levels of IL-4 were significantly higher in Exo-FBS-treated wells than in untreated cells (paired t-test, p = 0.001; Fig. 3).

Fig. 3
figure 3

Cytokine levels in culture supernatants of splenocytes obtained from collagen-induced arthritis mouse models. The spleen cells from three mice were isolated on day 48 after CII immunization (2 × 105 cells/96-well plate well) with or without ConA (5 μg/mL), or LPS (2.5 μg/mL). Each well was treated with medium (no-treatment, X), Exo-FBS, Exo-RA, or Exo-non-RA (n = 3). The exosomes and splenocytes were co-cultured at a ratio of 9 μg: 2 × 105. The levels of IL-6, IL-17, IL-4, IFN-γ, IL-2, and MCP-1 were analyzed in the supernatants of ConA-stimulated splenocytes, and the levels of TNF-α, KC, IL-10, IL-1α, IL-1β, MIP-2, IL-12p70, and RANTES were analyzed in LPS-stimulated splenocytes. Data are expressed as the mean ± standard error of the mean. To compare means from two related samples, the paired t-test was used. *, Significant (p < 0.05) differences from the control (X). CII: type II collagen

Full size image

The levels of IL-17, IL-10, and IL-1β were significantly lower (paired t-test, p = 0.026, p = 0.034, and p < 0.001, respectively) and the levels of IL-4 were significantly higher in Exo-RA-treated wells than in untreated cells (paired t-test, p = 0.034; Fig. 3).

The levels of IL-17 were significantly lower (paired t-test, p = 0.007) and the levels of IL-4 were significantly higher in Exo-non-RA-treated cells than in untreated cells (paired t-test, p = 0.04; Fig. 3).

In vivo assay

Assessment of the arthritis severity

On the last day of measurement (day 51), group C had the highest sum of arthritis score, followed by groups M, E, and F (Fig. 4A). There was no significant difference in the arthritis score of groups N, E, and F, however, group C and M had significantly higher scores than group N on the last day of measurement (arthritis score, day 51: ANOVA and Tukey’s test, p = 0.012, Fig. 4B).

Fig. 4
figure 4

Arthritis score, concentrations of anti-type II collagen antibody and C-telopeptide, and suppression test of supernatant from spleen cells in the experimental groups. A Sum of arthritis score. B Arthritis score on day 51. C Hind paw thickness. D Concentration of anti-chicken type II collagen antibody. E Concentration of anti-mouse type II collagen antibody. F Concentration of C-telopeptide. On day 52 or 53, spleens were harvested from all mice (n = 10/group). Splenocytes from each mouse were cultured in a 96-well plate (2 × 105 cells/well, final volume: 200 μL) with G CII, H ConA, or I LPS (100 μg/mL, 5 μg/mL, and 2.5 μg/mL respectively). Plates were incubated at 37 °C in 5% CO2. After 3 days, the BrdU assay was conducted. The stimulation index value (mean optical density of CII or mitogen-stimulated cultures/mean optical density of medium-only cultures) was calculated for each culture treatment. Data (mean ± standard error of the mean) were compared using one-way analysis of variance followed by Tukey’s multiple comparison post-hoc tests.*, Significant differences (p < 0.05) from the control (C group); #. Significant (p < 0.05) differences from the normal (N) group. CII: type II collagen, ConA: Concanavalin A, LPS: Lipopolysaccharide

Full size image

In hind paw thickness analysis, there was no significant difference between groups N, F, and M, however, groups C and E were significantly thicker paws than group N on the last day of measurement (hind paw thickness, day 49: ANOVA and Tukey’s test, p = 0.008; Fig. 4C).

Anti-CII antibody and serum C-telopeptide II levels

Although there was no statistical significance, the mean concentration of anti-chicken CII antibody was the highest in group C, followed by groups E, F, M, and N (Fig. 4D), while the mean concentration of anti-mouse CII antibody was the highest in group E, followed by groups C, F, M, and N (Fig. 4E). The mean concentration of c-telopeptide II was the highest in group C, followed by that in groups E, F, N, and M (Fig. 4F).

T cell proliferation test using splenocytes from experimental animals

T cell proliferation in response to CII or LPS treatment was not significantly different among groups. However, T cell proliferation in response to the ConA stimulus was significantly suppressed in group F compared to group C (ANOVA and Tukey’s test, p = 0.029; Fig. 4G–I).

Flow-cytometric determination of T cell subset, CD138 cells, and macrophage subset in the spleen

There was no significant difference in the CD4+:CD8+ cell ratio among the groups (Fig. 5A). CD138+ cell proportion was significantly lower in the F and N groups than in the C group (ANOVA and Tukey’s test, p < 0.001; Fig. 5B).

Fig. 5
figure 5

Flow-cytometric determination of T cell subsets, CD138 cells, macrophage subset, and the T helper cell subset in the spleen taken from the experimental groups. A CD4+T cells: CD8+T cells; B CD138+ cells; C CD64+ cells of CD45+ cells; D CD11c-CD206+ (M2) cells of CD45+CD64+ cells; E M1 (CD45+CD64+CD11c+CD206−) cells; F Treg (CD4+CD25+Foxp3+) cells; G Th17 (CD4+CD25+ROR-γt+) cells; H Treg:Th17 I Th1 (CD4+CD25+T-bet+) cells; J Th2 (CD4+CD25+GATA3+) cells; (K) Th1:Th2. Data obtained from experimental groups were compared using one-way analysis of variance followed by Tukey’s multiple comparison post-hoc tests (n = 6/group). *, Significant (p < 0.05) differences from the control (C group)

Full size image

Among the CD45+ cells, the proportion of CD64+ cells was significantly lower in groups E, F, M, and N than in C group (ANOVA and Tukey’s test, p < 0.001; Fig. 5C). The proportion of CD11c−CD206+ macrophages (M2) among the CD45+CD64+ cells was significantly higher in the F, M, and N groups than in the C and E groups (ANOVA and Tukey’s test, p < 0.001; Fig. 5D). The proportion of M1 (CD45+CD64+CD11c+CD206−) macrophages was significantly lower in the F than in C group (ANOVA and Tukey’s test, p = 0.012; Fig. 5E).

Flow-cytometric analysis of the T helper cell subset in the spleen

The ratio of Tregs (CD4+CD25+Foxp3+) was significantly lower in group M than in group C (p = 0.008), whereas it was not different in the other groups from group C (Fig. 5F). The proportion of Th17 (CD4+CD25+ROR-γt+) cells was significantly higher in group N than in group C (ANOVA and Tukey’s test, p = 0.001), whereas that in the other groups did not differ from that in group C (Fig. 5G). The Treg: Th17 ratio was significantly lower in group N than in group C (ANOVA and Tukey’s test, p = 0.031), while it was not different in the other groups from group C (Fig. 5H).

The proportion of Th1 (CD4+CD25+T-bet+) cells did not differ among the groups (Fig. 5I), and the proportion of Th2 (CD4+CD25+GATA3+) cells was significantly higher in groups E, F, and N than in group C and M (ANOVA and Tukey’s test, p < 0.001; Fig. 5J). The Th1:Th2 ratio was significantly different among the groups (ANOVA, p = 0.041); it was the highest in group C, followed by groups M, N, E, and F (Fig. 5K).

Cytokine levels in sera and knee joint extracts

Serum levels of IL-4 were significantly higher in group E and F than in group C (Kruskal–Wallis test, p < 0.001; Dunn’s test C vs E, p < 0.001 and C vs. F, p < 0.001; Fig. 6A). Serum levels of KC and TNF-α were significantly lower in group F and N than in group C (KC: Kruskal–Wallis test, p = 0.019; Dunn’s test C vs F, p = 0.04 and C vs N, p = 0.001; TNF-α: Kruskal–Wallis test, p < 0.001; Dunn’s test C vs F, p = 0.003 and C vs N, p = 0.001; Fig. 6B and C).

Fig. 6
figure 6

Various cytokine levels in serum and knee joint extract samples A Serum levels of IL-4. B Serum levels of KC. C Serum levels of TNF-α. D IFN-γ levels in knee joint extracts. E IL-12p70 levels in knee joint extracts. F TNF-α levels in knee joint extracts. Data obtained from experimental groups were compared using Kruskal–Wallis and Dunn’s tests (serum cytokines: n = 10/group, knee extracts: n = 8–10/group). *, Significant differences (p < 0.05) from the control (C group)

Full size image

The level of IFN-γ in knee joint extracts was significantly lower in groups F and M than in group C (Kruskal–Wallis test, p = 0.006; Dunn’s test C vs F, p = 0.024 and C vs M, p = 0.002; Fig. 6D). The level of IL-12p70 in knee joint extracts was significantly lower in group F, M, and N than in group C (Kruskal–Wallis test, p = 0.001; Dunn’s test C vs F, p = 0.016, C vs M, p = 0.042, and C vs N, p = 0.028; Fig. 6E). The level of TNF-α in knee joint extracts was significantly lower in group F and N than in group C (Kruskal–Wallis test, p = 0.029; Dunn’s test C vs F, p = 0.004 and C vs N, p = 0.01; Fig. 6F).

Histological evaluation of knee joint

The knee joints of mice from both the F and N groups showed lesser destruction of articular cartilage compared to group C (Fig. 7A). The histopathological scores of the knee joints of group F and N were significantly lower than those of group C (ANOVA and Tukey’s test, p < 0.001; Fig. 7B).

Fig. 7
figure 7

Histopathological examination of knee joint A Histopathology: representative knee joint sections of each group at day 52 or 53 after administration of primary immunization. Original magnification: ×100, arrowhead: severe cartilage destruction. B Score of cartilage damage; 0–4 (no damage to severe damage). Data obtained from experimental groups were compared using one-way analysis of variance followed by Tukey’s multiple comparison post-hoc tests (n = 10/group).*, Significant differences (p < 0.05) from the control (C group)

Full size image

Therefore, the administration of Exo-RA alleviated the progression of cartilage destruction in the CIA mouse model.

Figure 8 shows a summary of the schedule of animal experiments, the production process of Exo-RA, and cytokine changes in a mouse model of RA after Exo-RA administration.

Fig. 8
figure 8

Experimental schedule and changes in cytokines after Exo-RA treatment in a mouse model of RA. A Experimental schedule and experimental groups according to administered material. B Changes in cytokines after Exo-RA treatment in a mouse model of RA. CFA, complete Freund’s adjuvant; IFA, incomplete Freund’s adjuvant. iv: intravenous injection; ip: intraperitoneal injection; FBS: fetal bovine serum; Exo-RA: exosomes derived from the supernatant of 2 × 106 iMSCs primed with RA serum

Full size image

Discussions

In RA, the dysregulation of various cytokines appears to be due to Th17/Treg and M1/M2 imbalances [27]. Th17 and M1 cells are important sources of IL-1β, IL-17, and TNF-α, which induce inflammation and joint damage in RA [28]. IL-4, an anti-inflammatory cytokine, has a significantly decreased serum concentration in patients with RA compared to that in the healthy controls and plays an immunosuppressive and anti-osteoclastogenic role in RA modulation [29].

MSCs suppress innate and adaptive immune cells; they induce an anti-inflammatory state by inhibiting T and B cells, inducing Treg, and lowering proinflammatory cytokines such as TNF-α, IL-1β, and IL-6 [30]. In addition, activated MSC induces M2 activation by increasing IL-10 [31], and MSC promotes bone regeneration by suppressing osteoclast function. MSC administration in RA improved the immune balance by lowering TNF-α, IL-1β, IL-6, and IL-17 and increasing TGF-β1 and IL-10 [32].

After administration, MSC-derived exosomes did not change in response to the host microenvironment. Hence, in the present study, we provided MSCs with a host microenvironment to MSCs prior to obtaining exosomes.

NTA and analysis of the exosome marker CD81 revealed that Exo-RA had a significantly higher number of exosomes compared to Exo-FBS, and the amounts of TGF-β1 were significantly higher in Exo-RA than those in Exo-FBS. Based on these results, we found that the exosomes obtained from MSCs pre-educated in the patient's microenvironment (disease-condition-serum) were functionally advanced.

miRNAs such as miR-155-5p, miR-146a-5p, miR-10-5p, miR-142-3p, and miR-216a-5p are known to contribute to the immunomodulatory effect of MSCs and MSC-derived extracellular vesicles in autoimmune diseases [33,34,35]. In this study, there was no significant difference in the expression of miR-155-5p, miR-146a-5p, miR-10-5p, and miR-142-3p in equal concentrations of RNA from Exo-FBS and Exo-RA. There was no statistically significant difference in the expression levels of miR-155-5p, miR-146a-5p, miR-10-5p, miR-142-3p, and miR-216a-5p in equal concentrations of RNA from MSC-FBS and MSC-RA. However, the number of exosomes and the total amount of CD81 were significantly higher in Exo-RA than in Exo-FBS. Although priming with disease-condition-serum did not increase immunomodulation-specific miRNA expression in the RNA from exosomes or MSCs, it significantly increased exosome production from MSCs and induced superior therapeutic effects. Several studies have reported that MSC-derived exosomes show dose-dependent effects. For example, MSC-derived exosomes enhanced functional recovery in rat traumatic brain injury in a dose-dependent manner [36].

MSCs restore the immune balance via TGF-β and PGE2 [33]. PGE2 upregulates cAMP, inhibits the proinflammatory cytokines IL-12p70 and TNF-α, and induces the anti-inflammatory cytokines IL-4 and IL-10 [37]. In addition, cAMP promotes M2 macrophage and Th2 cell differentiation, and inhibits Th1 cell production. TGF-β is the main immunoregulatory cytokine produced by MSCs. Through the TGF-β/NF-kB pathway, the production of Th17 and Th1 decreases, and the production of Treg and Th2 increases [37]. Deregulated NF-κB activation contributes to the inflammatory response in RA [38]. TGF-β antagonizes the activation of important targets of proinflammatory stimuli of NF-κB in lymphocytes and macrophages [39]. Thus, the interaction of NF-κB and TGF-β signaling pathways may be important in RA progression and treatment.

In this experiment, it was difficult to observe significant changes in Tregs or Th17 cells following exosome administration; however, significant increases in Th2 and anti-inflammatory M2 macrophages were confirmed.

When splenocytes obtained from the CIA model (RA model) were stimulated with ConA or LPS, the levels of IL-17, IL-10, and IL-1β were significantly lower and the levels of IL-4 were significantly higher in Exo-RA-treated cells than in untreated cells.

Anti-chicken type II collagen antibody and C-telopeptide levels were expected to be significantly lower in group F than in the other groups. However, the difference between the groups was not statistically significant. However, when splenocytes were stimulated with ConA, the stimulation index was significantly lower in group F than in the other groups. Therefore, the immune cell response to ConA was significantly reduced.

Serum IL-4 levels and the proportion of Th2 (CD4+CD25+GATA3+) cells were significantly increased in the Exo-FBS and Exo-RA treatment groups than in the control group. Furthermore, the proportion of anti-inflammatory M2 cells was significantly increased in the Exo-FBS and Exo-RA treatment groups than in the control group. In addition, serum levels of KC and TNF-α and the levels of IFN-γ, IL-12p70, and TNF-α in the knee joint were significantly lower in the Exo-RA treatment group than in the control group. Moreover, the histopathological scores of the knee joints were significantly lower in the Exo-RA treatment group than in the control group.

TNF-α plays an important role in the pathogenesis of RA. In patients with RA, TNF-α is primarily produced by macrophages that are activated by synovial tissue inflammation and is capable of inducing the production of other proinflammatory cytokines [40]. Accordingly, TNF-α induces the synthesis of KC, which in turn acts as a neutrophil chemoattractant [41].

Therefore, in this study, a decrease in serum KC and TNF-α levels induced a reduction in the inflammatory response and recovery in the RA model.

IL-12p70 levels are elevated in both serum and synovial fluid of patients with RA [42]. IL-12 induces the production of other proinflammatory cytokines and IL-12 levels have been reported to reflect RA disease activity [42, 43]. IL-12p70 plays a major role in inducing Th1 cells by promoting the production of IFN-γ from T cells that infiltrate the joints of patients with RA [44].

Therefore, a decrease in the serum levels of KC and TNF-α, and in the levels of IL-12p70 and TNF-α in the joints induced a reduction in the inflammatory response and recovery from RA. MSC-derived extracellular vesicles suppress the proliferation and differentiation of B cells, and macrophages transform into an anti-inflammatory M2 phenotype via the PI3K-AKT pathway [33, 45, 46]. miRNA-155-5p and miRNA-216a-5p derived from MSC-derived extracellular vesicles contribute to this mechanism [33].

Regarding the clinical symptoms related to arthritis, the control, and Exo-FBS groups had significantly thicker paws than the normal group, whereas there was no difference in paw thickness between the Exo-RA group and the normal group. Compared with the control group, the Exo-RA group showed improved arthritis score sum and average foot thickness, but the difference was not statistically significant. It is believed that a higher dose or more frequent administration of exosomes is necessary to obtain a greater inhibitory effect on clinical symptoms.

In previous studies on MSC-derived exosomes related to RA, strategies to overexpress miRNAs have been used to enhance the therapeutic effect of exosomes. Because miR-192 is known to inhibit the growth of RA fibroblast-like synoviocytes, an MSC-derived exosome overexpressing miR-192-5p was constructed [47]. Because miR-150-5p significantly reduced the expression of MMP-14 and VEGF in RA fibroblast-like synoviocytes, an MSC-derived exosome overexpressing miR-150-5p was constructed [48]. When MSC-derived exosomes overexpressing miR-150-5p or miR-192 were applied to an RA model, the treatment effect was greater than that of MSC-derived exosomes alone [47, 48]. When MSC-derived exosome overexpressing miR-192-5p was administered, a significant decrease in serum TNF-α was observed in a RA model [47].

Our results suggest that exosomes derived from MSCs primed with disease-condition-serum are highly functional and that MSC-derived exosomes or exosomes derived from MSCs primed with disease-condition-serum shift immune cells to Th2 and M2 differentiation in the RA model. Furthermore, exosomes derived from MSCs primed with disease-condition-serum may alleviate cartilage damage by lowering the concentration of proinflammatory cytokines such as TNF-α, KC, and IL-12p70.

When applied to human medicine, patient serum can be used as an iMSC priming strategy to obtain more efficient exosomes for treatment of RA.

Conclusions

Exosomes derived from disease-condition-serum-primed iMSCs ameliorated cartilage damage in a RA model by enhancing TGF-β1 production, inducing Th2 and M2 polarization and lowering proinflammatory cytokines, TNF-α, KC, and IL-12p70 in the host. Patient-derived serum can be used as an iMSC priming strategy in the iMSC-derived exosome treatment of RA.

Availability of data and materials

The data used in this study are available from the corresponding author upon reasonable request.

Abbreviations

RA:

Rheumatoid arthritis

MSCs:

Mesenchymal stem cells

IFN-γ:

Interferon-γ

IL:

Interleukin

MSC-exosomes:

MSC-derived exosomes

hTERT :

Human telomerase reverse transcriptase

iMSCs:

Immortalized human adipose tissue-derived MSCs

Exo-FBS:

Exosomes derived from the supernatant of iMSCs

Exo-RA:

iMSCs primed with RA serum

Exo-non-RA:

iMSCs primed with non-RA serum

BCA:

Bicinchoninic acid

NTA:

Nanoparticle tracking analysis

TEM:

Transmission electron microscopy

TGF:

Transforming growth factor

miR:

MicroRNA

IACUC:

Institutional Animal Care and Use Committee

CII:

Chicken type II collagen

CIA:

Collagen-induced arthritis

ConA:

Concanavalin A

LPS:

Lipopolysaccharide

C-telopeptide II:

C-telopeptide of type II collagen

TNF-α:

Tumor necrosis factor-α

KC:

Keratinocyte chemoattractant

MCP-1:

Monocyte chemoattractant protein 1

MIP-2:

Macrophage inflammatory protein 2

RANTES:

Regulated upon activation normal T cell expressed and presumably secrete

MTX:

Methotrexate

M1:

M1 macrophages

M2:

M2 macrophages

Th:

T helper

Treg:

T regulatory cells

SEM:

Standard error of the mean

ANOVA:

One-way analysis of variance

cAMP:

Cyclic AMP

PI3K:

Phosphatidylinositol-3 kinase

NF-kB:

Nuclear factor kappa light chain enhancer of activated B cells

References

  1. Ma D, Xu K, Zhang G, Liu Y, Gao J, Tian M, Wei C, Li J, Zhang L. Immunomodulatory effect of human umbilical cord mesenchymal stem cells on T lymphocytes in rheumatoid arthritis. Int Immunopharmacol. 2019;74:105687.

    Article  CAS  PubMed  Google Scholar 

  2. Yu MB, Firek A, William HR, Langridge WHR. Predicting methotrexate resistance in rheumatoid arthritis patients. Inflammopharmacology. 2018;26:699–708.

    Article  CAS  PubMed  Google Scholar 

  3. Wang W, Zhou H, Liu L. Side effects of methotrexate therapy for rheumatoid arthritis: a systematic review. Eur J Med Chem. 2018;158:502–16.

    Article  CAS  PubMed  Google Scholar 

  4. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BAC, Tak PP, Gerrit Jan Wolbink GJ. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007;66:921–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun. 2010;11:180–210.

    Article  CAS  PubMed  Google Scholar 

  6. Liu J, Gao J, Liang Z, Gao C, Niu Q, Wu F, Zhang L. Mesenchymal stem cells and their microenvironment. Stem Cell Res Ther. 2022;13:429.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Figueroa FE, Carrión F, Villanueva S, Khoury M. Mesenchymal stem cell treatment for autoimmune diseases: a critical review. Biol Res. 2012;45:269–77.

    Article  PubMed  Google Scholar 

  8. Jasim SA, Yumashev AV, Abdelbasset WK, Margiana R, Markov A, Suksatan W, Pineda B, Thangavelu L, Ahmadi SH. Shining the light on clinical application of mesenchymal stem cell therapy in autoimmune diseases. Stem Cell Res Ther. 2022;13:101.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Madrigal M, Rao KS, Riordan NH. A review of therapeutic effects of mesenchymal stem cell secretions and induction of secretory modification by different culture methods. J Transl Med. 2014;12:260.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Silva-Carvalho AÉ, Rodrigues LP, Schiavinato JL, Alborghetti MR, Bettarello G, Simões BP, Neves FAR, Panepucci RA, de Carvalho JL, Saldanha-Araujo F. GVHD-derived plasma as a priming strategy of mesenchymal stem cells. Stem Cell Res Ther. 2020;11:156.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Vulliet PR, Greeley M, Halloran SM, MacDonald KA, Kittleson MD. Intra-coronary arterial injection of mesenchymal stromal cells and microinfarction in dogs. Lancet. 2004;363:783–4.

    Article  PubMed  Google Scholar 

  12. Gong M, Bi Y, Jiang W, Zhang Y, Chen L, Hou N, Liu Y, Wei X, Chen J, Li T. Immortalized mesenchymal stem cells: an alternative to primary mesenchymal stem cells in neuronal differentiation and neuroregeneration associated studies. J Biomed Sci. 2011;18:87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Tsai CC, Chen CL, Liu HC, Lee YT, Wang HW, Hou LT, Hung SC. Overexpression of hTERT increases stem-like properties and decreases spontaneous differentiation in human mesenchymal stem cell lines. J Biomed Sci. 2010;17:64.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Kim HY, Kim TJ, Kang L, Kim YJ, Kang MK, Kim J, Ryu JH, Hyeon T, Yoon BW, Ko SB, Kim BS. Mesenchymal stem cell-derived magnetic extracellular nanovesicles for targeting and treatment of ischemic stroke. Biomaterials. 2020;243:119942.

    Article  CAS  PubMed  Google Scholar 

  15. Mardpour S, Hamidieh AA, Taleahmad S, Sharifzad F, Taghikhani A, Baharvand H. Interaction between mesenchymal stromal cell-derived extracellular vesicles and immune cells by distinct protein content. J Cell Physiol. 2019;234:8249–58.

    Article  CAS  PubMed  Google Scholar 

  16. Wu P, Zhang B, Shi H, Qian H, Xu W. MSC-exosome: a novel cell-free therapy for cutaneous regeneration. Cytotherapy. 2018;20:291–301.

    Article  PubMed  Google Scholar 

  17. Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol. 2014;32:252–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Bo Y, Xiaomin Z, Xiaorong L. Exosomes derived from mesenchymal stem. Int J Mol Sci. 2014;15:4142–57.

    Article  Google Scholar 

  19. Amit M, Carpenter MK, Inokuma MS, Chiu CP, Harris CP, Waknitz MA, Itskovitz-Eldor J, Thomson JA. Clonally derived human embryonic stem cell lines maintain pluripotency and proliferative potential for prolonged periods of culture. Dev Biol. 2000;227:271–8.

    Article  CAS  PubMed  Google Scholar 

  20. Baxter MA, Wynn RF, Jowitt SN, Wraith JE, Fairbairn LJ, Bellantuono I. Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion. Stem Cells. 2004;22:675–82.

    Article  CAS  PubMed  Google Scholar 

  21. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, Wright WE. Extension of life-span by introduction of telomerase into normal human cells. Science. 1998;279:349–52.

    Article  CAS  PubMed  Google Scholar 

  22. Choi EW, Shin IS, Song JW, Lee M, Yun TW, Yang J, Choi KS, Kim SJ. Effects of transplantation of CTLA4Ig-overexpressing adipose tissue-derived mesenchymal stem cells in mice with sustained severe rheumatoid arthritis. Cell Transplant. 2016;25:243–59.

    Article  PubMed  Google Scholar 

  23. Choi EW, Yun TW, Song JW, Lee M, Yang J, Choi KS. Preventive effects of CTLA4Ig-overexpressing adipose tissue-derived mesenchymal stromal cells in rheumatoid arthritis. Cytotherapy. 2015;17:271–82.

    Article  CAS  PubMed  Google Scholar 

  24. Choi EW, Song JW, Ha N, Choi YI, Kim S. CKD-506, a novel HDAC6-selective inhibitor, improves renal outcomes and survival in a mouse model of systemic lupus erythematosus. Sci Rep. 2018;8:17297.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Choi EW, Kim HJ, Jung YC, Go HS, Seong JK. Effects of high fat diet-induced obesity on pathophysiology, immune cells, and therapeutic efficacy in systemic lupus erythematosus. Sci Rep. 2022;12:18532.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Choi EW, Lee KW, Park H, Kim H, Lee JH, Song JW, Yang J, Kwon Y, Kim TM, Park JB, Kim S. Therapeutic effects of anti-CD154 antibody in cynomolgus monkeys with advanced rheumatoid arthritis. Sci Rep. 2018;8:2135.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Fukui S, Iwamoto N, Takatani A, Igawa T, Shimizu T, Umeda M, Nishino A, Horai Y, Hirai Y, Koga T, Kawashiri SY, Tamai M, Ichinose K, Nakamura H, Origuchi T, Masuyama R, Kosai K, Yanagihara K, Kawakami A. M1 and M2 monocytes in rheumatoid arthritis: a contribution of imbalance of M1/M2 monocytes to osteoclastogenesis. Front Immunol. 2018;8:1958.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Van Raemdonck K, Umar S, Palasiewicz K, Volkov S, Volin MV, Arami S, Chang HJ, Zanotti B, Sweiss N, Shahrara S. CCL21/CCR7 signaling in macrophages promotes joint inflammation and Th17-mediated osteoclast formation in rheumatoid arthritis. Cell Mol Life Sci. 2020;77:1387–99.

    Article  PubMed  Google Scholar 

  29. Chen Z, Bozec A, Ramming A, Schett G. Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis. Nat Rev Rheumatol. 2019;15:9–17.

    Article  CAS  PubMed  Google Scholar 

  30. Yoshizumi Y, Yukawa H, Iwaki R, Fujinaka S, Kanou A, Kanou Y, Yamada T, Nakagawa S, Ohara T, Nakagiri K, Ogihara Y, Tsutsui Y, Hayashi Y, Ishigami M, Baba Y, Ishikawa T. Immunomodulatory effects of adipose tissue-derived stem cells on concanavalin A-induced acute liver injury in mice. Cell Med. 2016;9:21–33.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Saldaña L, Bensiamar F, Vallés G, Mancebo FJ, García-Rey E, Vilaboa N. Immunoregulatory potential of mesenchymal stem cells following activation by macrophage-derived soluble factors. Stem Cell Res Ther. 2019;10:58.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Li YJ, Chen Z. Cell-based therapies for rheumatoid arthritis: opportunities and challenges. Ther Adv Musculoskelet Dis. 2022;14:1759720X221100294.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Yang C, Sun J, Tian Y, Li H, Zhang L, Yang J, Wang J, Zhang J, Yan S, Xu D. Immunomodulatory effect of MSCs and MSCs-derived extracellular vesicles in systemic lupus erythematosus. Front Immunol. 2021;12:714832.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Di Trapani M, Bassi G, Midolo M, Gatti A, Kamga PT, Cassaro A, Carusone R, Adamo A, Krampera M. Differential and transferable modulatory effects of mesenchymal stromal cell-derived extracellular vesicles on T, B and NK cell functions. Sci Rep. 2016;6:24120.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Wang Y, Liang J, Qin H, Ge Y, Du J, Lin J, Zhu X, Wang J, Xu J. Elevated expression of miR-142-3p is related to the pro-inflammatory function of monocyte-derived dendritic cells in SLE. Arthritis Res Ther. 2016;18:263.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Zhang Y, Zhang Y, Chopp M, Zhang ZG, Mahmood A, Xiong Y. Mesenchymal stem cell-derived exosomes improve functional recovery in rats after traumatic brain injury: a dose-response and therapeutic window study. Neurorehabil Neural Repair. 2020;34:616–26.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Boniface K, Bak-Jensen KS, Li Y, Blumenschein WM, McGeachy MJ, McClanahan TK, McKenzie BS, Kastelein RA, Cua DJ, de Waal MR. Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J Exp Med. 2009;206:535–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Samimi LN, Farhadi E, Tahmasebi MN, Jamshidi A, Vaziri AS, Mahmoudi M. NF-κB signaling in rheumatoid arthritis with focus on fibroblast-like synoviocytes. Autoimmun Highlights. 2020;11:11.

    Article  Google Scholar 

  39. Bitzer M, von Gersdorff G, Liang D, Dominguez-Rosales A, Beg AA, Rojkind M, Böttinger EP. A mechanism of suppression of TGF–β/SMAD signaling by NF-κB/RelA. Genes Dev. 2000;14:187–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Farrugia M, Baron B. The role of TNF-α in rheumatoid arthritis: a focus on regulatory T cells. J Clin Transl Res. 2016;2:84–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Vieira SM, Lemos HP, Grespan R, Napimoga MH, Dal-Secco D, Freitas A, Cunha TM, Verri WA Jr, Souza-Junior DA, Jamur MC, Fernandes KS, Oliver C, Silva JS, Teixeira MM, Cunha FQ. A crucial role for TNF-α in mediating neutrophil influx induced by endogenously generated or exogenous chemokines, KC/CXCL1 and LIX/CXCL5. Br J Pharmacol. 2009;158:779–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Petrovic-Rackov L, Pejnovic N. Clinical significance of IL-18, IL-15, IL-12 and TNF-α measurement in rheumatoid arthritis. Clin Rheumatol. 2006;25:448–52.

    Article  PubMed  Google Scholar 

  43. Kim WU, Min SY, Cho ML, Youn J, Min JK, Lee SH, Park SH, Cho CS, Kim HY. The role of IL-12 in inflammatory activity of patients with rheumatoid arthritis (RA). Clin Exp Immunol. 2000;119:175–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Morita Y, Yamamura M, Nishida K, Harada S, Okamoto H, Inoue H, Ohmoto Y, Modlin RL, Makino H. Expression of interleukin-12 in synovial tissue from patients with rheumatoid arthritis. Arthritis Rheum. 1998;41:306–14.

    Article  CAS  PubMed  Google Scholar 

  45. Adamo A, Brandi J, Caligola S, Delfino P, Bazzoni R, Carusone R, Cecconi D, Giugno R, Manfredi M, Robotti E, Marengo E, Bassi G, Kamga PT, Collo GD, Gatti A, Mercuri A, Arigoni M, Olivero M, Calogero RA, Krampera M. Extracellular vesicles mediate mesenchymal stromal cell-dependent regulation of B Cell PI3K-AKT signaling pathway and actin cytoskeleton. Front Immunol. 2019;10:446.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Xin D, Li T, Chu X, Ke H, Yu Z, Cao L, Bai X, Liu D, Wang Z. Mesenchymal stromal cell-derived extracellular vesicles modulate microglia/macrophage polarization and protect the brain against hypoxia-ischemic injury in neonatal mice by targeting delivery of miR-21a-5p. Acta Biomater. 2020;113:597–613.

    Article  CAS  PubMed  Google Scholar 

  47. Zheng J, Zhu L, In II, Chen Y, Jia N, Zhu W. Bone marrow-derived mesenchymal stem cells-secreted exosomal microRNA-192-5p delays inflammatory response in rheumatoid arthritis. Int Immunopharmacol. 2020;78:105985.

    Article  CAS  PubMed  Google Scholar 

  48. Chen Z, Wang H, Xia Y, Yan F, Lu Y. Therapeutic potential of mesenchymal cell-derived miRNA-150-5p-expressing exosomes in rheumatoid arthritis mediated by the modulation of MMP14 and VEGF. J Immunol. 2018;201:2472–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank the histopathology staff of the Laboratory Animal Research Center, SBRI, and Samsung Medical Center for their technical support and assistance.

Funding

This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (Ministry of Science and ICT) awarded to Eun Wha Choi (NRF-2021R1A2C2004224). The funding body played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Author information

Authors and Affiliations

  1. Department of Veterinary Clinical Pathology, College of Veterinary Medicine and Institute of Veterinary Science, Kangwon National University, 1 Kangwondaehak-gil, Chuncheon, Gangwon-do, 24341, Republic of Korea

    Eun Wha Choi, I.-Rang Lim & Ji Hong Park

  2. Bioanalysis Center, GenNBio Inc., 700, Daewangpangyo-ro, Bundang-guGyeonggi-do, Seongnam-si, 13488, Republic of Korea

    Jiwoo Song & Bongkum Choi

  3. GenNBio Inc., 80, Deurimsandan 2-ro, Cheongbuk-eup, Pyeongtaek-si, Gyeonggi-do, 17796, Republic of Korea

    Sungjoo Kim

Authors
  1. Eun Wha Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I.-Rang Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ji Hong Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jiwoo Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bongkum Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sungjoo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

EWC designed the study, performed the experiments, analyzed the data, and wrote the manuscript. I-RL and JHP performed the experiments and collected and analyzed the data. JS, BC, and SK performed the experiments (animal experiments) and collected the data, and all authors contributed to the discussion and editing of the manuscript. All the authors have read and approved the final version of the manuscript.

Corresponding author

Correspondence to Eun Wha Choi.

Ethics declarations

Ethics approval and consent to participate

The study was reviewed and approved by the IACUC of Kangwon National University (KW-210824-1) and the IACUC of GenNBio (GN-IACUC-22-01-10) as follows; for in vitro functional test: (1) Title of the approved project: The effects of advanced mesenchymal stem cell-derived materials on rheumatoid arthritis (2) Name of the institutional approval committee: IACUC of Kangwon National University (3) Approval number: KW-210824-1 (4) Date of approval: August 30, 2021/for in vivo study: (1) Title of the approved project: The therapeutic effect of advanced exosome in mouse rheumatoid arthritis model (2) Name of the institutional approval committee: IACUC of GenNBio (3) Approval number: GN-IACUC-22-01-10 (4) Date of approval: January 14, 2022.

Consent for publication

Not applicable.

Competing interests

JS, BC, and SK are employees of GenNBio Inc. The remaining authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Choi, E.W., Lim, IR., Park, J.H. et al. Exosomes derived from mesenchymal stem cells primed with disease-condition-serum improved therapeutic efficacy in a mouse rheumatoid arthritis model via enhanced TGF-β1 production. Stem Cell Res Ther 14, 283 (2023). https://doi.org/10.1186/s13287-023-03523-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13287-023-03523-0

Keywords

Stem Cell Research & Therapy

ISSN: 1757-6512